Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer.

BMC Cancer · 2025 · PMC11905668 · PMID 40075310

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Homologous recombination repair (HRR)-related gene (e.g., BRCA1 , BRCA2 , ATM ) mutations showed a trend towards shorter PFS and OS times, but there were no statistically significant differences (Supplementary Fig. 2 C, D ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.